Bovine mammary gland
... the elevation in phagocytic cells, lymphocytes, immunoglobulins and Lf These changes occur too slowly and their antibacterial action is compromised by other normal events of involution. Treatment of glands at or near drying off with colchicine, endotoxin or the combination of the two compounds resul ...
... the elevation in phagocytic cells, lymphocytes, immunoglobulins and Lf These changes occur too slowly and their antibacterial action is compromised by other normal events of involution. Treatment of glands at or near drying off with colchicine, endotoxin or the combination of the two compounds resul ...
Printable Issue
... is enormous,” says Michael Longaker, MD, co-director of Stanford’s Institute for Stem Cell Biology and Regenerative Medicine. “About 80 million incisions a year in this country heal with a scar, and that’s just on the skin alone. Internal scarring is responsible for many medical conditions, includin ...
... is enormous,” says Michael Longaker, MD, co-director of Stanford’s Institute for Stem Cell Biology and Regenerative Medicine. “About 80 million incisions a year in this country heal with a scar, and that’s just on the skin alone. Internal scarring is responsible for many medical conditions, includin ...
Detection of fg/mL Levels of GM
... differentiation of myeloid progenitor cells into immune cells. Chemotherapy patients are sometimes given recombinant GM-CSF (molgramostim or sargramostim) to increase production of white blood cells and prevent neutropenia. The basal levels of GM-CSF in blood are in the fg/mL range, and are therefor ...
... differentiation of myeloid progenitor cells into immune cells. Chemotherapy patients are sometimes given recombinant GM-CSF (molgramostim or sargramostim) to increase production of white blood cells and prevent neutropenia. The basal levels of GM-CSF in blood are in the fg/mL range, and are therefor ...
Evidence for neuroinflammation in Alzheimer`s disease
... do not have a specific enough anti-inflammatory action and are actually inhibiting the beneficial phagocytic effects of microglia on Aβ. TNFα is a proinflammatory cytokine released by microglia and has been implicated as having a central Therapeutic strategies for targeting role in the neuroinflamm ...
... do not have a specific enough anti-inflammatory action and are actually inhibiting the beneficial phagocytic effects of microglia on Aβ. TNFα is a proinflammatory cytokine released by microglia and has been implicated as having a central Therapeutic strategies for targeting role in the neuroinflamm ...
Failure of T cell immunity
... always fully representative of the in vivo situation. On the other hand, cells obtained from chronically infected patients show very similar deficiencies compared to the ‘stunned’ T-cells16. These T cells are characterized as exhausted T-cells, signified through their inability to produce effector ...
... always fully representative of the in vivo situation. On the other hand, cells obtained from chronically infected patients show very similar deficiencies compared to the ‘stunned’ T-cells16. These T cells are characterized as exhausted T-cells, signified through their inability to produce effector ...
Reprogramming of Myeloid Compartments Supporting Tissue
... inflammation play a critical role in regulating T cell function. However, mechanisms governing the generation of these cells remain unclear, and need to be further defined. Using a DSSinduced colitis and recovery model, we characterized the dynamic changes within myeloid compartments and the emergen ...
... inflammation play a critical role in regulating T cell function. However, mechanisms governing the generation of these cells remain unclear, and need to be further defined. Using a DSSinduced colitis and recovery model, we characterized the dynamic changes within myeloid compartments and the emergen ...
Journal of Autoimmunity
... need exists to develop a biomarker that will indicate underlying autoimmunity, changes as the disease progresses, and can be followed serially for evidence of therapeutic efficacy. In T1D subjects, frequencies of islet antigen reactive CD4þ, and CD8þ T-cells [9e12] are higher compared to healthy dono ...
... need exists to develop a biomarker that will indicate underlying autoimmunity, changes as the disease progresses, and can be followed serially for evidence of therapeutic efficacy. In T1D subjects, frequencies of islet antigen reactive CD4þ, and CD8þ T-cells [9e12] are higher compared to healthy dono ...
M261 MHC class I antigen presentation April 17, 2000
... MHC polypeptides (a and b) are synthesized on ER and are chaperoned to a specialized antigen loading compartment by invariant chain (Ii); invariant chain serves two purposes, it functions as a chaperone and occupies the peptide binding groove to stabilize MHC class II and prevent other peptides (sel ...
... MHC polypeptides (a and b) are synthesized on ER and are chaperoned to a specialized antigen loading compartment by invariant chain (Ii); invariant chain serves two purposes, it functions as a chaperone and occupies the peptide binding groove to stabilize MHC class II and prevent other peptides (sel ...
Here - European Macrophage and Dendritic Cell Society
... the category “immunology, microbiology and virology”. All this is meant to emphasize that immunology is very close to our hearts. Needless to say that many of us have had a strong and long-standing interest in macrophages and dendritic cells. This year´s EMDS meeting focusses on the interaction of m ...
... the category “immunology, microbiology and virology”. All this is meant to emphasize that immunology is very close to our hearts. Needless to say that many of us have had a strong and long-standing interest in macrophages and dendritic cells. This year´s EMDS meeting focusses on the interaction of m ...
Genetic variation in HLA and susceptibility to acute myeloid
... different HLA alleles possess different peptide-binding repertoires. HLA class I proteins present peptides from intra-cellular proteins (including invasive viruses) to TCR on CD8 (cytotoxic) T cells leading to immune mechanisms which destroy the cell. It is noteworthy that HLA proteins, in particula ...
... different HLA alleles possess different peptide-binding repertoires. HLA class I proteins present peptides from intra-cellular proteins (including invasive viruses) to TCR on CD8 (cytotoxic) T cells leading to immune mechanisms which destroy the cell. It is noteworthy that HLA proteins, in particula ...
Skeletal System
... Because there are fewer efferent vessels draining the node than there afferent vessels feeding it, the flow of lymph through the node stagnates somewhat, allowing time for the lymphocytes and macrophages to carry out their protective ...
... Because there are fewer efferent vessels draining the node than there afferent vessels feeding it, the flow of lymph through the node stagnates somewhat, allowing time for the lymphocytes and macrophages to carry out their protective ...
Vasculitis: Attack of the Leukocytes
... anti-inflammatory medication, called methotrexate, and the value of inhibiting a proinflammatory protein called TNF(tumor necrosis factor alpha). Experimental procedures that have been helpful in treating some cases of vasculitis include: plasmapheresis; intravenous gamma globulin; and the use of ...
... anti-inflammatory medication, called methotrexate, and the value of inhibiting a proinflammatory protein called TNF(tumor necrosis factor alpha). Experimental procedures that have been helpful in treating some cases of vasculitis include: plasmapheresis; intravenous gamma globulin; and the use of ...
Chapter 4 - Dr. Jerry Cronin
... Protect and insulate internal organs Compartmentalize and transport Energy reserves and immune responses ...
... Protect and insulate internal organs Compartmentalize and transport Energy reserves and immune responses ...
Soluble Fas and Fas ligand provide new information on metastasis
... of circulating soluble Fas and FasL has not been examined. In the present study, we measured the concentrations of circulating soluble Fas and FasL in patients with small cell lung cancer (SCLC), as they have higher sensitivity to chemotherapeutic agents than non-small cell lung cancer (NSCLC) patie ...
... of circulating soluble Fas and FasL has not been examined. In the present study, we measured the concentrations of circulating soluble Fas and FasL in patients with small cell lung cancer (SCLC), as they have higher sensitivity to chemotherapeutic agents than non-small cell lung cancer (NSCLC) patie ...
Immune Cognition, Micro-evolution,
... When a pathogen invades our bodies, some of our immune cells that recognize this pathogen will start replicating, a process during which mutation occurs. One interesting aspect of the cellular reproduction (cloning) process in the immune system is that cells are subjected to error during cloning. In ...
... When a pathogen invades our bodies, some of our immune cells that recognize this pathogen will start replicating, a process during which mutation occurs. One interesting aspect of the cellular reproduction (cloning) process in the immune system is that cells are subjected to error during cloning. In ...
Umbilical cord blood transplantation for acute myeloid leukemia
... predominates when more than one cord is infused is still the topic of significant investigation. In addition, it is possible that we may be able to ‘select’ which cord predominates by manipulation such as coculture with complement and upregulation of chemokine (C-X-C motif) receptor 4 (CXCR4). This ...
... predominates when more than one cord is infused is still the topic of significant investigation. In addition, it is possible that we may be able to ‘select’ which cord predominates by manipulation such as coculture with complement and upregulation of chemokine (C-X-C motif) receptor 4 (CXCR4). This ...
Melanoma stem cells: not rare, but well done
... cells that comprised the hematopoietic system. Since the first identification of hematopoietic stem cells, similar cells of mesodermal, ectodermal, and endodermal lineages have been recognized in adult tissues. In skin, for instance, epithelial stem cells have been found in the basal layer of the ep ...
... cells that comprised the hematopoietic system. Since the first identification of hematopoietic stem cells, similar cells of mesodermal, ectodermal, and endodermal lineages have been recognized in adult tissues. In skin, for instance, epithelial stem cells have been found in the basal layer of the ep ...
Complement in skin diseases
... C7 and C9. They are also a source of several cytokines, which are important for the synthesis of complement proteins and regulation of their release. It has recently been found that TNF alpha increases C9 synthesis and thus contributes to the formation of membrane attack complex (61). The involvemen ...
... C7 and C9. They are also a source of several cytokines, which are important for the synthesis of complement proteins and regulation of their release. It has recently been found that TNF alpha increases C9 synthesis and thus contributes to the formation of membrane attack complex (61). The involvemen ...
Page 1 of 27 Functionally distinct subsets of human
... produced during different types of inflammatory responses. Based on differential expression of the chemokine receptors CCR6, CXCR3, CCR4 and CCR10, four subsets of CD4+CD45RO+CD25– CD127+ TH cells can be defined in the peripheral blood of healthy donors: CXCR3+ TH1 cells that produce IFN-γ, CXCR3–CC ...
... produced during different types of inflammatory responses. Based on differential expression of the chemokine receptors CCR6, CXCR3, CCR4 and CCR10, four subsets of CD4+CD45RO+CD25– CD127+ TH cells can be defined in the peripheral blood of healthy donors: CXCR3+ TH1 cells that produce IFN-γ, CXCR3–CC ...
Cancer immunotherapy
Cancer immunotherapy (immuno-oncology) is the use of the immune system to treat cancer. Immunotherapies fall into three main groups: cellular, antibody and cytokine. They exploit the fact that cancer cells often have subtly different molecules on their surface that can be detected by the immune system. These molecules, known as cancer antigens, are most commonly proteins, but also include molecules such as carbohydrates. Immunotherapy is used to provoke the immune system into attacking the tumor cells by using these antigens as targets.Antibody therapies are the most successful immunotherapy, treating a wide range of cancers. Antibodies are proteins produced by the immune system that bind to a target antigen on the cell surface. In normal physiology the immune system uses them to fight pathogens. Each antibody is specific to one or a few proteins. Those that bind to cancer antigens are used to treat cancer. Cell surface receptors are common targets for antibody therapies and include the CD20, CD274, and CD279. Once bound to a cancer antigen, antibodies can induce antibody-dependent cell-mediated cytotoxicity, activate the complement system, or prevent a receptor from interacting with its ligand, all of which can lead to cell death. Multiple antibodies are approved to treat cancer, including Alemtuzumab, Ipilimumab, Nivolumab, Ofatumumab, and Rituximab.Cellular therapies, also known as cancer vaccines, usually involve the removal of immune cells from the blood or from a tumor. Immune cells specific for the tumor are activated, cultured and returned to the patient where the immune cells attack the cancer. Cell types that can be used in this way are natural killer cells, lymphokine-activated killer cells, cytotoxic T cells and dendritic cells. The only cell-based therapy approved in the US is Dendreon's Provenge, for the treatment of prostate cancer.Interleukin-2 and interferon-α are examples of cytokines, proteins that regulate and coordinate the behaviour of the immune system. They have the ability to enhance anti-tumor activity and thus can be used as cancer treatments. Interferon-α is used in the treatment of hairy-cell leukaemia, AIDS-related Kaposi's sarcoma, follicular lymphoma, chronic myeloid leukaemia and malignant melanoma. Interleukin-2 is used in the treatment of malignant melanoma and renal cell carcinoma.